ROCO
6612
Market cap96mUSD
Nov 12, Last price
88.10TWD
Name
Icares Medicus Inc
Chart & Performance
P/E
29.19
P/S
3.50
EPS
3.02
Div Yield, %
0.25%
Shrs. gr., 5y
—
Rev. gr., 5y
14.06%
Revenues
860m
+42.01%
Net income
103m
+5.52%
CFO
-11m
L-58.03%
Dividend
Jul 08, 20240.22 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ICARES Medicus, Inc., a nano-medical material company, focuses on the research and development, manufacture, and sale of ophthalmic medical materials in Taiwan and internationally. It provides ophthalmic medical materials, including intraocular lens for the treatment of cataract, myopia, hyperopia, presbyopia, or astigmatism; and surgical implantation systems, as well as related technical services. ICARES Medicus, Inc. was incorporated in 2011 and is based in Zhubei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||